Induction of periarthritis by oral administration of 6-sulfanilamidoindazole and its treatment in rats.
D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D002738:Chloroquine / Q000627:therapeutic use; D003023:Cloxacillin / Q000627:therapeutic use; D006830:Hydralazine / Q000627:therapeutic use; D006854:Hydrocortisone / Q000627:therapeutic use*; D007213:Indomethacin / Q000627:therapeutic use*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009020:Morphine / Q000627:therapeutic use; D010113:Oxyphenbutazone / Q000627:therapeutic use; D010248:Paramethasone / Q000627:therapeutic use; D010489:Periarthritis / Q000139:chemically induced* / Q000188:drug therapy*; D010653:Phenylbutazone / Q000627:therapeutic use*; D051381:Rats; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013449:Sulfonamides; D062367:ortho-Aminobenzoates / Q000627:therapeutic use
D013449:Sulfonamides; D062367:ortho-Aminobenzoates; D006830:Hydralazine; D009020:Morphine; D002738:Chloroquine; D015122:Mercaptopurine; D010653:Phenylbutazone; D010113:Oxyphenbutazone; D003023:Cloxacillin; D001241:Aspirin; D013442:Sulfinpyrazone; D010248:Paramethasone; D006854:Hydrocortisone; D007213:Indomethacin; D008727:Methotrexate